Slide 1: Q2 2024 results
Q2 2024 results Solid performance exceeding outlook July 31, 2024
Slide 2: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: Certain statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1
Slide 3: Q2 2024: Solid results ahead of outlook
Q2 2024: Solid results ahead of outlook Growth $496 m ($502 m CER) Solid Q2 2024 net sales and adj. diluted EPS results ahead of outlook Net sales • +2% CER sales growth excluding NeuMoDx +1% CER • Sample technologies (+1% CER), Diagnostic solutions (+5% CER, +8% CER excl. NeuMoDx) vs. Q2 2023 and P
Slide 4: Q2 2024: Sales performance and key developments
Q2 2024: Sales performance and key developments Sales by product group Key developments (In $ millions at actual rates) +1% Sample • Solid sales growth in automated consumables CER(1) technologies • Weaker instrument sales amid cautious customer spending 495 496 • +11% CER growth, another quarter ab
Slide 5: Q2 2024: Strong quarter for operating profitability
Q2 2024: Strong quarter for operating profitability Adj. operating income margin Adj. EPS ahead of Q2 2024 outlook Adj. operating SG&A improvements vs. Q2 2023 +1.0 ppt income 28.4% 27.4% Non- operating 19% adj. tax rate in line with outlook income $0.55 Adj. EPS(1) ($0.55 CER vs. $0.52 CER outlook)
Slide 6: H1 2024: Significant improvement in cash flow generation
H1 2024: Significant improvement in cash flow generation Cash flow Debt maturity overview(1) (in $ millions) In $ millions Q2 2024 Q2 2023 Change Operating cash flow 167 111 +49% 613 Purchases of PP&E -38 -29 +31% 500 113 Free cash flow 129 82 +56% Likely repayment in 2025(2) 500 150 In $ millions H
Slide 7: Q2 2024: Portfolio developments
Q2 2024: Portfolio developments Human ID / Forensics: QIAstat-Dx: Improving public safety Facilitate rapid and informed decisions FBI partnership in the U.S. New U.S. panel launches in July 2024 • Development of QIAcuity assays for improved • Gastrointestinal: New panel for detection of 16 quantific
Slide 8: 2024: Outlook perspectives
2024: Outlook perspectives Net sales outlook (CER) Adj. EPS outlook (CER) Full-year 2024 outlook update ≥$2.0 bn ≥$2.16 ~ +$15 m ≥$1.985 bn Net sales ~ -$30 m ≥$2.10 ~ +$0.04 ≥$1.985 bn CER ~ +$0.02 Adj. diluted EPS ≥$2.16 CER Initial H1 NeuMoDx Updated Initial H1 NeuMoDx Updated 2024 2024 decision(
Slide 9: 2024: Updating full-year outlook
2024: Updating full-year outlook As of July 31, 2024 Q3 2024 outlook FY 2024 outlook Net sales >$495 million CER >$1.985 billion CER Anticipated currency impact Adverse impact of ~ -1 ppt Adverse impact of ~ -1 ppt (Previously ≥$2.0 bn CER) Adjusted diluted EPS >$0.55 CER >$2.16 CER Anticipated curr
Slide 10: Appendix
Appendix July 31, 2024 Q2 2024 results 10
Slide 11: Q3 and FY 2024: Outlook and assumptions
Q3 and FY 2024: Outlook and assumptions (As of July 31, 2024) Q3 2024 outlook FY 2024 outlook Net sales >$495 million CER >$1.985 billion CER Anticipated currency impact(1) Adverse impact of ~ -1 ppt Adverse impact of ~ -1 ppt Adjusted diluted EPS(2) >$0.55 CER >$2.16 CER Anticipated currency impact
Slide 12: Q2 2024: Consolidated Statements of Income (unaudited)
Q2 2024: Consolidated Statements of Income (unaudited) (In $ thousands, except share data) Three months ended Three months ended June 30, 2024 June 30, 2023 Net sales 496,347 494,857 Cost of sales: Cost of sales 446,371 166,637 Acquisition-related intangible amortization 15,212 16,068 Total cost of
Slide 13: H1 2024: Consolidated Statements of Income (unaudited)
H1 2024: Consolidated Statements of Income (unaudited) (In $ thousands, except share data) Six months ended Six months ended June 30, 2024 June 30, 2023 Net sales 955,143 980,255 Cost of sales: Cost of sales 598,105 328,543 Acquisition-related intangible amortization 31,285 32,084 Total cost of sale
Slide 14: 2024: Quarterly sales by product group
2024: Quarterly sales by product group Q1 2024 Q2 2024 Q3 2024 Q4 2024 FY 2024 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sample technologies 155 -11% -10% 164 -1% 1% 318 -6% -5% Diagnostic solutions(1) 170
Slide 15: 2024: Quarterly sales by product type, customer class and region
2024: Quarterly sales by product type, customer class and region Q1 2024 Q2 2024 Q3 2024 Q4 2024 FY 2024 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Product type Consumables and related 409 -5% -4% 442 2% 3%
Slide 16: Q2 and H1 2024: Reconciliation to adjusted results (unaudited)
Q2 and H1 2024: Reconciliation to adjusted results (unaudited) (In $ millions, except EPS) Net Gross Operating Pre-tax Income Tax Net Diluted sales profit income income tax rate income EPS* Second quarter 2024 Reported results 496.3 34.8 (228.4) (223.5) 40.0 18% (183.5) (0.83) Adjustments Business i
Slide 17: Q2 and H1 2024: Footnotes for reconciliation to adjusted results
Q2 and H1 2024: Footnotes for reconciliation to adjusted results (unaudited) a. Results for 2024 include charges for the restructuring program initiated in Q2 2024, as well as acquisition projects, including the continued integration of Verogen Inc. Results for 2023 include acquisition projects incl
Slide 18: 2024: Quarterly income statement summary
2024: Quarterly income statement summary (In $ millions, unless indicated) (Diluted EPS in $ per share) Q1 2024 Q2 2024 Q3 2024 Q4 2024 FY 2024 Net sales 458.8 496.3 955.1 Net sales (CER) 461.7 502.0 963.8 Gross profit 291.0 34.8 325.8 Gross profit margin 63.4% 7.0% 34.1% Adjusted gross profit 307.8
Slide 19: Consolidated Balance Sheets
Consolidated Balance Sheets December 31, December 31, (In $ thousands, except par value) June 30, 2024 2023 (In $ thousands, except par value) June 30, 2024 2023 Assets (unaudited) Liabilities and Equity (unaudited) Cash and cash equivalents 533,644 668,084 Current portion of long-term debt 492,699
Slide 20: Consolidated Statements of Cash Flows (unaudited)
Consolidated Statements of Cash Flows (unaudited) Six months ended Six months ended (In $ thousands) June 30, 2024 June 30, 2023 (In $ thousands) June 30, 2024 June 30, 2023 Cash flows from operating activities: Cash flows from financing activities: Net (loss) income (102,787) 165,821 Capital repaym
Slide 21: Q2 and H1 2024: Currency impact
Q2 and H1 2024: Currency impact Net sales Net sales Currency exposure Change (In $ millions / Actual) (CER) (As % of CER sales) (In $ millions) Q2 2024 U.S. dollar 271.3 271.3 54% 0.0 Euro 95.3 96.4 19% 1.1 British pound 19.5 19.4 4% -0.2 Japanese yen 8.9 10.1 2% 1.2 Other currencies 101.3 104.9 21%
Slide 22: Employees as of June 30, 2024
Employees as of June 30, 2024 Europe / Middle Asia Pacific / Total Total Americas East / Africa Japan / ROW Q2 2024 Q1 2024 Change Production 386 1,177 138 1,701 1,710 -1% R&D 220 775 58 1,053 1,056 0% Sales 572 847 743 2,162 2,168 0% Marketing 67 197 68 332 340 -2% Administration 79 420 156 655 660
Slide 23: Your contacts
Your contacts Dr. Domenica Martorana Associate Director Calendar Global Investor Relations Q3 2024 results November 2024 Phone: +49 2103 29 11244 Q4 2024 results February 2025 E-mail: domenica.martorana@qiagen.com Alexandra Koenig Share information Coordinator NYSE: QGEN Investor Relations Frankfurt